Berenberg Bank downgraded shares of PTC (NASDAQ:PTC – Free Report) from a buy rating to a hold rating in a research report sent to investors on Friday morning, Marketbeat.com reports. They currently have $196.00 price target on the technology company’s stock, down from their prior price target of $210.00.
Other analysts also recently issued reports about the stock. Rosenblatt Securities reiterated a “buy” rating and issued a $195.00 price target on shares of PTC in a research report on Thursday, October 10th. Robert W. Baird increased their target price on shares of PTC from $216.00 to $226.00 and gave the stock an “outperform” rating in a report on Tuesday, October 22nd. Piper Sandler raised their price target on PTC from $177.00 to $182.00 and gave the company a “neutral” rating in a research note on Thursday, August 1st. Royal Bank of Canada restated an “outperform” rating and set a $202.00 price objective on shares of PTC in a research note on Thursday, August 1st. Finally, StockNews.com cut PTC from a “buy” rating to a “hold” rating in a research note on Monday, August 5th. Five research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $200.67.
Read Our Latest Analysis on PTC
PTC Stock Performance
Insider Activity at PTC
In other PTC news, Director Janice Chaffin sold 4,000 shares of the company’s stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $171.34, for a total value of $685,360.00. Following the completion of the transaction, the director now owns 44,137 shares of the company’s stock, valued at $7,562,433.58. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 1.17% of the stock is currently owned by insiders.
Institutional Trading of PTC
Institutional investors have recently added to or reduced their stakes in the stock. Los Angeles Capital Management LLC bought a new stake in PTC in the third quarter worth approximately $269,000. Legacy Capital Wealth Partners LLC bought a new position in shares of PTC during the third quarter valued at about $302,000. Covestor Ltd boosted its stake in shares of PTC by 70.8% in the 3rd quarter. Covestor Ltd now owns 193 shares of the technology company’s stock worth $35,000 after buying an additional 80 shares during the last quarter. Atria Investments Inc boosted its position in PTC by 33.8% in the third quarter. Atria Investments Inc now owns 2,455 shares of the technology company’s stock worth $444,000 after purchasing an additional 620 shares during the last quarter. Finally, Equitable Trust Co. boosted its holdings in shares of PTC by 2.2% in the 3rd quarter. Equitable Trust Co. now owns 3,602 shares of the technology company’s stock worth $651,000 after buying an additional 79 shares during the last quarter. 95.14% of the stock is currently owned by institutional investors.
PTC Company Profile
PTC Inc operates as software company in the Americas, Europe, and the Asia Pacific. The company provides Windchill, a suite that manages all aspects of the product development lifecycle(PLM) that provides real-time information sharing, dynamic data visualization, collaborate across geographically distributed teams, and enabling manufacturers to elevate product development, manufacturing, and field service processes; ThingWorx, a platform for Industrial Internet of Things; ServiceMax, a field service management solutions enable companies to asset uptime with optimized in-person and remote service and technician productivity with mobile tools.
Read More
- Five stocks we like better than PTC
- Insider Buying Explained: What Investors Need to Know
- Intel: Is Now the Time to Be Brave?
- Stock Market Sectors: What Are They and How Many Are There?
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- What is the NASDAQ Stock Exchange?
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for PTC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC and related companies with MarketBeat.com's FREE daily email newsletter.